News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
News ViiV ownership shifts as Pfizer sells its stake Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.
News Shionogi puts up to $600m behind BioVersys antibiotics Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.
News Shionogi aims to buy tobacco giant's pharma unit for $1bn Shionogi has reached a $1.04bn agreement to buy Torii, the pharma subsidiary of Japan Tobacco, as it tries to meet an ambitious sales target.
News Shionogi gets approval in Japan for ADHD digital therapeutic Shionogi will market the EndeavorRide app, originally licensed from Akili, in Japan following its approval by the MHLW regulator.
News Maze gets new Pompe partner after FTC blocks Sanofi deal Five months after Sanofi backed away from a proposed deal with Maze Therapeutics on a Pompe disease therapy after an antitrust challenge, Shionogi has snapped up the drug.
News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
